ZOMARTEM

This brand name is authorized in Nigeria.

Active ingredients

The drug ZOMARTEM contains a combination of these active pharmaceutical ingredients (APIs):

1	Artemether UNII C7D6T3H22J - ARTEMETHER
	Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
	Read more about Artemether
2	Lumefantrine UNII F38R0JR742 - LUMEFANTRINE
	Read more about Lumefantrine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-0392	Tablet	ZOMARTEM 20/120 TABLET TAB 20 mg; 120 mg 1 X 24	ZOMARTEM 20/120 TABLET ZOMARTEM ARTEMETHER 20MG, LUMEFANTRINE 120MG OTC TABLET 1 X 24 ANTIMALARIA PHARMEZONE LIMITED 14, FRANCIS OKEDEJI STREET, OLD BODIJA, IBADAN, OYO STATE JIANGSU RUINIAN QIANJIN PHARMACEUTICAL CO. LTD CHUANBU VILLAGE, DINGSHU TOWN, YIXING CITY, JIANGSU PROVINCE, CHINA GMP- SATIS; LR- SATIS; FEES- PAID; NP:NA 04/02/2019 C4-0392	30/01/2020
C4-0393	Dispersible tablet	ZOMARTEM DISPERSIBLE TABLET TAB_ORALLY_DIS 20 mg; 120 mg 2 X 6	ZOMARTEM DISPERSIBLE TABLET ZOMARTEM ARTEMETHER 20MG, LUMEFANTRINE 120MG OTC TABLET 2 X 6 ANTIMALARIA PHARMEZONE LIMITED 14, FRANCIS OKEDEJI STREET, OLD BODIJA, IBADAN, OYO STATE JIANGSU RUINIAN QIANJIN PHARMACEUTICAL CO. LTD CHUANBU VILLAGE DINGSHU TOWN, YIXING CITY, JIANGSU PROVINCE, CHINA GMP- SATIS; LR- SATIS; FEES- PAID; NP:NA 04/02/2019 C4-0393	30/01/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
P01BF01	Artemether and lumefantrine	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BF Artemisinin and derivatives, combinations
Discover more medicines within P01BF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	C4-0392, C4-0393